首页> 外文OA文献 >Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial

【2h】

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial

机译：Everolimus Plus Exemestan在绝经后妇女患有激素受体阳性，人表皮生长因子受体2阴性局部晚期或转移性乳腺癌的疗效和安全性：单臂，IIIB的结果结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Hans Tesch; Oliver Stoetzer; Thomas Decker; Christian M. Kurbacher; Frederik Marmé; Andreas Schneeweiss; Christoph Mundhenke; Andrea Distelrath; Peter A. Fasching; Michael P. Lux; Diana Lüftner; Peyman Hadji; Wolfgang Janni; Mathias Muth; Julia Kreuzeder; Claudia Quiering; Florin-Andrei Taran;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial [J] . Tesch Hans, Stoetzer Oliver, Decker Thomas, International Journal of Cancer =: Journal International du Cancer . 2019,第4期

机译：Everolimus Plus Exemestane在绝经后妇女患有激素受体阳性，人体表皮生长因子受体2阴性局部晚期或转移性乳腺癌的疗效和安全性：单臂，IIIB阶段的结果的结果
2. BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTORPOSITIVE (ER plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC) [J] . Bachelot Thomas, Villanueva Cristian, Royce Melanie, The Breast : . 2015,第Suppla3期

机译：BOLERO-4：第2阶段，开放式，多中心，单臂试验，研究了绝经后患者（PTS）和雌激素受体阳性（ER + ），人类表皮生长因子受体2-阴性（HER2-）转移性或局部晚期无法治疗的乳腺癌（BC）
3. BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTORPOSITIVE (ER plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC) [J] . Bachelot Thomas, Villanueva Cristian, Royce Melanie, The Breast : . 2015,第Suppla3期

机译：Bolero-4：第2阶段，开放标签，多中心，单手臂试验研究一线血酮（前夕）与雌激素受体展（PTS）在绝经后患者（PTS）中的Letrozole（Let）的疗效和安全性（ER Plus ），人表皮生长因子受体2阴性（HER2-）转移性或局部先进的不可切除的乳腺癌（BC）
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm phase IIIB 4EVER trial [O] . Hans Tesch, Oliver Stoetzer, Thomas Decker, -1

机译：依维莫司+依西美坦在激素受体阳性人表皮生长因子受体2-阴性局部晚期或转移性乳腺癌的绝经后妇女中的疗效和安全性：单臂IIIB 4EVER期试验的结果
7. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial [O] . Peyman Hadji, Oliver Stoetzer, Thomas Decker, 2019

机译：哺乳动物催乳素抑制抑制对蛋白质阳性晚期晚期乳腺癌骨髓骨骼骨骼健康的影响，接受Everolimus和Exemestane在IIIB阶段的4EG 4

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial

著录项

引文网络

相似文献

相关主题

期刊订阅